Assembly Biosciences appoints new CFO; shareholders approve stock plan share increases

ASSEMBLY BIOSCIENCES, INC.

Jeanette M. Bjorkquist appointed principal financial officer effective June 5, 2025; Jason A. Okazaki remains CEO.
Shareholders approved Amendment No. 1 to 2018 Stock Incentive Plan: shares reserved increased by 375,000 to 1,478,333.
Amendment No. 2 approved: 225,000 additional shares for performance-based vesting retention grants.
ESPP Amendment No. 1 approved: shares reserved increased from 164,500 to 225,000.
All 10 director nominees elected; Ernst & Young ratified as auditor for FY 2025.

item 5.02item 5.07item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeanette M. Bjorkquist

principal financial officer

ASMB · ASSEMBLY BIOSCIENCES, INC.

Effective: 2025-06-05
Filed: Jun 09, 2025 23:59 UTC

On June 5, 2025, the Board of Directors appointed Jeanette M. Bjorkquist to serve as the Company’s principal financial officer in addition to her role as principal accounting officer.

Role change

Jason A. Okazaki

principal executive officer

ASMB · ASSEMBLY BIOSCIENCES, INC.

Effective: 2025-06-05
Successor: Jeanette M. Bjorkquist
Filed: Jun 09, 2025 23:59 UTC

Ms. Bjorkquist succeeds Jason A. Okazaki, who previously served as both the Company’s principal executive officer and principal financial officer.

Source: SEC EDGAR

accession 0000950170-25-083830

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.